secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-06-17T20:06:04+00:00
Accession:  0001104659-26-075130
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal shareholders approve 2026 equity plans; Dr. Taub transitions to consultant role
--------------------------------------------------------------------------------

- Stockholders approved 2026 Stock Plan and 2026 Employee Stock Purchase Plan at annual meeting.
- Dr. Rebecca Taub to transition from employee to consultant effective July 1, 2026; annual fee $100,000.
- Board adopted Nonqualified Deferred Compensation Plan effective Aug 1, 2026 for key management and non-employee directors.
- All director nominees re-elected; say-on-pay approved with 97% of votes for.
- PricewaterhouseCoopers ratified as auditor for FY2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000110465926075130/0001104659-26-075130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000110465926075130/tm2617490d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer